SOD1 Silencing in Motoneurons or Glia Rescues Neuromuscular Function in ALS Mice

Overview

Journal Ann Clin Transl Neurol

Specialty Neurology

Date 2015 Mar 10

PMID 25750921

Citations 38

Authors

Elisabeth Dirren

Julianne Aebischer

Cylia Rochat

Christopher Towne

Bernard L Schneider

Patrick Aebischer

Affiliations

Soon will be listed here.

Abstract

Objective: Amyotrophic lateral sclerosis is an incurable disorder mainly characterized by motoneuron degeneration. Mutations in the superoxide dismutase 1 (SOD1) gene account for 20% of familial forms of the disease. Mutant SOD1 exerts multiple pathogenic effects through the gain of toxic properties in both neurons and glial cells. Here, we compare AAV-based gene therapy suppressing expression of mutant SOD1 in either motoneurons or astrocytes.

Methods: AAV vectors encoding microRNA against human SOD1 were administered to (G93) (A)SOD1 mice either by intracerebroventricular injections in pups or by lumbar intrathecal injections in adults. Vector systems were designed to suppress SOD1 expression predominantly in either spinal motoneurons or astrocytes. Electrophysiological and behavioral tests were performed on treated animals to evaluate disease progression.

Results: Following vector injection in (G93) (A)SOD1 pups, efficient silencing of SOD1 expression was achieved in motoneurons and/or astrocytes. Most complete protection of motor units was obtained when targeting human SOD1 predominantly in motoneurons. Suppressing SOD1 mainly in astrocytes led to preserved muscle innervation despite only partial protection of spinal motoneurons. In both cases, injection in pups led to full recovery of neuromuscular function and significantly prolonged survival. Vector injections in adult mice also achieved significant protection of neuromuscular function, which was highest when motoneurons were targeted.

Interpretation: These results suggest that AAV-mediated SOD1 silencing is an effective approach to prevent motoneuron degeneration caused by SOD1 mutation. AAV vectors suppressing SOD1 in motoneurons delay disease onset and show effective neuroprotection. On the other hand, AAV-based SOD1 silencing in astrocytes rescues neuromuscular function following initial denervation.

Citing Articles

The Neuroprotective Effect of the X Protein of Orthobornavirus Bornaense Type 1 in Amyotrophic Lateral Sclerosis.

Tournezy J, Leger C, Klonjkowski B, Gonzalez-Dunia D, Szelechowski M, Garenne A Int J Mol Sci. 2024; 25(23).

PMID: 39684507 PMC: 11641280. DOI: 10.3390/ijms252312789.

Astrocyte-Neuron Interactions Contributing to Amyotrophic Lateral Sclerosis Progression.

Jensen B Adv Neurobiol. 2024; 39:285-318.

PMID: 39190080 DOI: 10.1007/978-3-031-64839-7_12.

Why should we care about astrocytes in a motor neuron disease?.

Dittlau K, Van Den Bosch L Front Mol Med. 2024; 3:1047540.

PMID: 39086676 PMC: 11285655. DOI: 10.3389/fmmed.2023.1047540.

In vivo and ex vivo gene therapy for neurodegenerative diseases: a promise for disease modification.

Ebrahimi P, Davoudi E, Sadeghian R, Zadeh A, Razmi E, Heidari R Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(10):7501-7530.

PMID: 38775852 DOI: 10.1007/s00210-024-03141-4.

as a model to study autophagy in neurodegenerative diseases induced by proteinopathies.

Santarelli S, Londero C, Soldano A, Candelaresi C, Todeschini L, Vernizzi L Front Neurosci. 2023; 17:1082047.

PMID: 37274187 PMC: 10232775. DOI: 10.3389/fnins.2023.1082047.

References

Raoul C, Abbas-Terki T, Bensadoun J, Guillot S, Haase G, Szulc J . Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med. 2005; 11(4):423-8. DOI: 10.1038/nm1207. View

Scott S, Kranz J, Cole J, Lincecum J, Thompson K, Kelly N . Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler. 2008; 9(1):4-15. DOI: 10.1080/17482960701856300. View

Rothstein J . Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol. 2009; 65 Suppl 1:S3-9. DOI: 10.1002/ana.21543. View

Lasiene J, Yamanaka K . Glial cells in amyotrophic lateral sclerosis. Neurol Res Int. 2011; 2011:718987. PMC: 3135155. DOI: 10.1155/2011/718987. View

Foust K, Salazar D, Likhite S, Ferraiuolo L, Ditsworth D, Ilieva H . Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Mol Ther. 2013; 21(12):2148-59. PMC: 3863799. DOI: 10.1038/mt.2013.211. View

Henkel J, Beers D, Zhao W, Appel S . Microglia in ALS: the good, the bad, and the resting. J Neuroimmune Pharmacol. 2009; 4(4):389-98. DOI: 10.1007/s11481-009-9171-5. View

Wang H, Yang B, Qiu L, Yang C, Kramer J, Su Q . Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis. Hum Mol Genet. 2013; 23(3):668-81. PMC: 3888258. DOI: 10.1093/hmg/ddt454. View

Lepore A, Rauck B, Dejea C, Pardo A, Rao M, Rothstein J . Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat Neurosci. 2008; 11(11):1294-301. PMC: 2656686. DOI: 10.1038/nn.2210. View

Freischmidt A, Muller K, Zondler L, Weydt P, Volk A, Losdorfer BoZic A . Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers. Brain. 2014; 137(Pt 11):2938-50. DOI: 10.1093/brain/awu249. View

10.

Rosen D, Siddique T, Patterson D, Figlewicz D, Sapp P, Hentati A . Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993; 362(6415):59-62. DOI: 10.1038/362059a0. View

11.

Boillee S, Yamanaka K, Lobsiger C, Copeland N, Jenkins N, Kassiotis G . Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006; 312(5778):1389-92. DOI: 10.1126/science.1123511. View

12.

Dirren E, Towne C, Setola V, Redmond Jr D, Schneider B, Aebischer P . Intracerebroventricular injection of adeno-associated virus 6 and 9 vectors for cell type-specific transgene expression in the spinal cord. Hum Gene Ther. 2013; 25(2):109-20. DOI: 10.1089/hum.2013.021. View

13.

Yamanaka K, Chun S, Boillee S, Fujimori-Tonou N, Yamashita H, Gutmann D . Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci. 2008; 11(3):251-3. PMC: 3137510. DOI: 10.1038/nn2047. View

14.

Jaarsma D, Teuling E, Haasdijk E, De Zeeuw C, Hoogenraad C . Neuron-specific expression of mutant superoxide dismutase is sufficient to induce amyotrophic lateral sclerosis in transgenic mice. J Neurosci. 2008; 28(9):2075-88. PMC: 6671838. DOI: 10.1523/JNEUROSCI.5258-07.2008. View

15.

Ralph G, Radcliffe P, Day D, Carthy J, Leroux M, Lee D . Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med. 2005; 11(4):429-33. DOI: 10.1038/nm1205. View

16.

Wang L, Gutmann D, Roos R . Astrocyte loss of mutant SOD1 delays ALS disease onset and progression in G85R transgenic mice. Hum Mol Genet. 2010; 20(2):286-93. DOI: 10.1093/hmg/ddq463. View

17.

Pun S, Santos A, Saxena S, Xu L, Caroni P . Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nat Neurosci. 2006; 9(3):408-19. DOI: 10.1038/nn1653. View

18.

Gurney M, Pu H, Chiu A, Dal Canto M, Polchow C, Alexander D . Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994; 264(5166):1772-5. DOI: 10.1126/science.8209258. View

19.

Kanning K, Kaplan A, Henderson C . Motor neuron diversity in development and disease. Annu Rev Neurosci. 2010; 33:409-40. DOI: 10.1146/annurev.neuro.051508.135722. View

20.

Al-Chalabi A, Jones A, Troakes C, King A, Al-Sarraj S, van den Berg L . The genetics and neuropathology of amyotrophic lateral sclerosis. Acta Neuropathol. 2012; 124(3):339-52. DOI: 10.1007/s00401-012-1022-4. View